CMS published the final rule, CMS-4215-F, on 5 November. It sets out in regulation how the Medicare Drug Price Negotiation Program will work from initial price applicability year 2029 onward. The first years of the program, 2026 to 2028, were run through program instructions and guidance, and that authority is expiring, CMS said. The rule takes effect on 5 December 2026.
For each year from 2029, CMS will select up to 20 drugs covered under Part D or paid under Part B. A primary manufacturer that is willing to take part must sign a negotiation agreement no later than 28 February after the selected drugs are published. Negotiation runs through written offers and counteroffers, and CMS will publish and explain each maximum fair price. A drug can leave the program once a generic or biosimilar is approved and marketed in a 'bona fide' way.
The rule closes what CMS calls a loophole for fixed-combination drugs. When a manufacturer adds an ingredient that creates a new formulation and a new route of administration, such as hyaluronidase, CMS will group the product with the same holder's original drug. The rule also sets a temporary price floor for qualifying small biotech drugs in 2029 and 2030, and lets CMS take the existing negotiated price into account when a drug is renegotiated.
For Part D plan sponsors, the rule confirms that each selected drug that is a covered Part D drug must be on plan formularies while a maximum fair price applies, and that plans may remove one only as the regulation allows. The negotiated price paid for a selected drug may not exceed the maximum fair price plus dispensing fees.
Read the source
Centers for Medicare & Medicaid Services · Regulator · 5 Nov 2026. This is an original brief based on the linked publication. Company statements and forecasts are attributed to their source.



